表1_重度哮喘患者生物制剂治疗前T2生物标志物组合与生物制剂反应关联

数据集获取（Figshare）

• 源站标题：Table_1_Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.docx
• DOI：10.3389/fimmu.2024.1361891.s002
• 发布日期：2024-04-22
• 文件数：1 个
• 文件总体积：19.25 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Association_between_pre-biologic_T2-biomarker_combinations_and_response_to_biologics_in_patients_with_severe_asthma_docx/25663473

命令行下载

curl -L -o "Table_1_Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.docx" "https://ndownloader.figshare.com/files/45782346"

文件清单

• Table_1_Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.docx（19.25 KB）

文件总体积 19.25 KB（源站 API 实测）。

数据说明

BackgroundTo date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials.
AimTo elucidate the associations of pre-biologic individual biomarker levels or their combinations with pre-to-post biologic changes in asthma outcomes in real-life.
MethodsThis was a registry-based, cohort study using data from 23 countries, which shared data with the International Severe Asthma Registry (May 2017-February 2023). The investigated biomarkers (highest pre-biologic levels) were immunoglobulin E (IgE), blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO). Pre- to approximately 12-month post-biologic change for each of three asthma outcome domains (i.e. exacerbation rate, symptom control and lung function), and the association of this change with pre-biologic biomarkers was investigated for individual and combined biomarkers.
ResultsOverall, 3751 patients initiated biologics and were included in the analysis. No association was found between pre-biologic BEC and pre-to-post biologic change in exacerbation rate for any biologic class. However, higher pre-biologic BEC and FeNO were both associated with greater post-biologic improvement in FEV1 for both anti-IgE and anti-IL5/5R, with a trend for anti-IL4Rα. Mean FEV1 improved by 27-178 mL post-anti-IgE as pre-biologic BEC increased (250 to 1000 cells/µL), and by 43-216 mL and 129-250 mL post-anti-IL5/5R and -anti-IL4Rα, respectively along the same BEC gradient. Corresponding improvements along a FeNO gradient (25-100 ppb) were 41-274 mL, 69-207 mL and 148-224 mL for anti-IgE, anti-IL5/5R, and anti-IL4Rα, respectively. Higher baseline BEC was also associated with lower probability of uncontrolled asthma (OR 0.392; p=0.001) post-biologic for anti-IL5/5R. Pre-biologic IgE was a poor predictor of subsequent pre-to-post-biologic change for all outcomes assessed for all biologics. The combination of BEC + FeNO marginally improved the prediction of post-biologic FEV1 increase (adjusted R2: 0.751), compared to BEC (adjusted R2: 0.747) or FeNO alone (adjusted R2: 0.7

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2024.1361891.s002（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Association_between_pre-biologic_T2-biomarker_combinations_and_response_to_biologics_in_patients_with_severe_asthma_docx/25663473）。